Elizabeth Garrett-Mayer to Disease-Free Survival
This is a "connection" page, showing publications Elizabeth Garrett-Mayer has written about Disease-Free Survival.
Connection Strength
0.297
-
Phase II trial of tipifarnib as maintenance therapy in first complete remission in adults with acute myelogenous leukemia and poor-risk features. Clin Cancer Res. 2008 May 15; 14(10):3077-82.
Score: 0.070
-
Lymphovascular space invasion in uterine corpus cancer: What is its prognostic significance in the absence of lymph node metastases? Gynecol Oncol. 2016 08; 142(2):278-82.
Score: 0.030
-
Cervical esophageal cancer: a population-based study. Head Neck. 2015 Jun; 37(6):808-14.
Score: 0.027
-
Randomized phase II study of two schedules of flavopiridol given as timed sequential therapy with cytosine arabinoside and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia. Haematologica. 2012 Nov; 97(11):1736-42.
Score: 0.023
-
Efficacy of bevacizumab plus erlotinib for advanced hepatocellular carcinoma and predictors of outcome: final results of a phase II trial. Oncology. 2012; 82(2):67-74.
Score: 0.023
-
High-dose fractionated radiotherapy to 80 Gy for stage I-II medically inoperable non-small-cell lung cancer. J Med Imaging Radiat Oncol. 2010 Dec; 54(6):554-61.
Score: 0.021
-
Capromab pendetide scanning has a potential role in optimizing patient selection for salvage cryosurgical ablation of the prostate. Urology. 2010 Nov; 76(5):1162-7.
Score: 0.021
-
Six-year experience: long-term disease control outcomes for partial breast irradiation using MammoSite balloon brachytherapy. Am J Surg. 2010 Feb; 199(2):204-9.
Score: 0.019
-
Re: Adaptive therapy for androgen-independent prostate cancer: a randomized selection trial of four regimens. J Natl Cancer Inst. 2008 May 07; 100(9):681-2; author reply 682-3.
Score: 0.017
-
Adjuvant weekly docetaxel for patients with high risk prostate cancer after radical prostatectomy: a multi-institutional pilot study. J Urol. 2007 May; 177(5):1777-81.
Score: 0.016
-
Clinical outcome following autologous and allogeneic blood and marrow transplantation for relapsed diffuse large-cell non-Hodgkin's lymphoma. Biol Blood Marrow Transplant. 2006 Sep; 12(9):965-72.
Score: 0.015
-
Graft-versus-host reactions and the effectiveness of donor lymphocyte infusions. Biol Blood Marrow Transplant. 2006 Apr; 12(4):414-21.
Score: 0.015